“The breadth of those knowledge displays our technique to advance numerous modalities for difficult-to-treat cancers,” mentioned Jay Bradner , M.D., govt vp, Analysis and Improvement, and chief scientific officer at Amgen. “These ESMO outcomes underscore our management in oncology, contributing vital developments with each investigational and established therapies. Guided by a deep understanding of most cancers biology and leveraging incisive therapeutics, we will goal dominant drivers of illness with unprecedented precision.”
Key displays embrace:
- First findings from the Section 1b examine of LUMAKRAS ® plus Vectibix ® together with FOLFIRI in first-line sufferers with KRAS G12C-mutated metastatic colorectal most cancers (mCRC).
- Section 1 dose escalation and preliminary dose enlargement knowledge from AMG 193 chosen for a presidential symposium session.
- First-in-human examine of xaluritamig in males with metastatic castration-resistant prostate most cancers (mCRPC).
For extra data on the Amgen abstracts, see under.
Abstracts and Presentation Occasions:
Amgen Sponsored Abstracts
LUMAKRAS ® (sotorasib) plus Vectibix ® (panitumumab)
- Sotorasib (soto) + panitumumab (pani) and FOLFIRI within the first line (1L) setting for KRAS-G12C mutated metastatic colorectal most cancers (mCRC): Security and efficacy from the part 1b CodeBreaK 101 examine
Summary #505O, Proffered Paper Oral Session: 2, Madrid Auditorium – Corridor 2, Sunday, September 15 from 3: 05 – 3:15 p.m. CEST
AMG 193
- Section 1 dose escalation and preliminary dose enlargement outcomes of AMG 193, an MTA-cooperative PRMT5 inhibitor, in sufferers (pts) with MTAP-deleted strong tumors
Summary #3482, Proffered Paper Oral Session: Presidential Symposium III: Eyes to the Future, Barcelona Auditorium – Corridor 2, Monday, September 16 from 16:30 – 18:15 p.m. CEST
Xaluritamig
- C irculating tumor cell (CTC) enumeration and total survival (OS) in males with metastatic castration-resistant prostate most cancers (mCRPC) handled with xaluritamig
Summary #1610P, Poster, September 15 - Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune remedy, in sufferers with metastatic castration-resistant prostate most cancers (mCRPC): Preliminary outcomes from dose enlargement cohorts in a Section 1 examine
Summary #1598P, Poster, September 15
LUMAKRAS ® (sotorasib) for NSCLC
- Sotorasib long-term scientific outcomes in pre-treated KRAS G12C-mutated superior NSCLC: pooled evaluation from the CodeBreaK scientific trials
Summary #1305P, Poster, September 14 - Scientific traits and therapeutic sequences of KRAS G12C superior Non-Small Cell Lung Most cancers (aNSCLC) sufferers (pts) handled by sotorasib within the French post-marketing authorization early entry (post-MA EA)
Summary #1307P, Poster, September 14
Bemarituzumab
- Fibroblast progress issue receptor 2 isoform IIIb (FGFR2b) protein overexpression and biomarker overlap in sufferers with superior gastric or gastroesophageal junction most cancers (GC/GEJC)
Summary #1420P, Poster, September 16
Investigator Sponsored Research
Vectibix ® (panitumumab)
- **mRNA profiling as a biomarker of prognosis and response to first-line remedy in metastatic colorectal most cancers: discovery and validation of a gene expression signature in three randomized trials
Summary #581P, Poster, September 16 - Circulating tumor DNA driving anti-EGFR rechallenge remedy in metastatic colorectal most cancers: the RASINTRO potential multicenter examine
Summary #517P, Poster, September 16 - Potential validation of the metastatic colon most cancers rating (mCCS) in sufferers with RAS wild-type metastatic colorectal most cancers handled with first-line panitumumab plus FOLFIRI/FOLFOX: Remaining outcomes of the non-interventional examine VALIDATE
Summary #585P, Poster, September 16
About LUMAKRAS ® /LUMYKRAS ® (sotorasib)
LUMAKRAS acquired accelerated approval from the U.S. Meals and Drug Administration (FDA) on Might 28, 2021 . The U.S. FDA accomplished its assessment of Amgen’s supplemental New Drug Software (sNDA) searching for full approval of LUMAKRAS ® on December 26, 2023 , which resulted in a whole response letter. As well as, the FDA concluded that the dose comparability postmarketing requirement (PMR) issued on the time of LUMAKRAS accelerated approval, to match the protection and efficacy of LUMAKRAS 960 mg day by day dose versus a decrease day by day dose, has been fulfilled. 960 mg once-daily is the indicated dose for sufferers with KRAS G12C-mutated NSCLC underneath accelerated approval. The U.S. FDA additionally issued a brand new PMR for an extra confirmatory examine to help full approval that will probably be accomplished no later than February 2028 .
About Metastatic Colorectal Most cancers and the KRAS G12C Mutation
Colorectal most cancers (CRC) is the second main reason behind most cancers deaths worldwide, comprising 10% of all most cancers diagnoses. 1 It’s also the third mostly recognized most cancers globally. 2
KRAS mutations are among the many commonest genetic alterations in colorectal cancers, with the KRAS G12C mutation current in roughly 3-5% of colorectal cancers. 3-5
About Superior Non-Small Cell Lung Most cancers and the KRAS G12C Mutation
Lung most cancers is the main reason behind cancer-related deaths worldwide, and it accounts for extra deaths worldwide than colon most cancers, breast most cancers and prostate most cancers mixed. 6
KRAS G12C is the commonest KRAS mutation in NSCLC. 7 About 13% of sufferers with non-squamous NSCLC harbor the KRAS G12C mutation. 8
About CodeBreaK
The CodeBreaK scientific improvement program for Amgen’s drug sotorasib is designed to review sufferers with a sophisticated strong tumor with the KRAS G12C mutation and deal with the longstanding unmet medical want for these cancers.
Amgen additionally has a number of Section 1b research investigating sotorasib monotherapy and sotorasib mixture remedy throughout numerous superior strong tumors (CodeBreaK 101) open for enrollment. 9 A Section 2 randomized examine evaluating sotorasib in sufferers with stage IV KRAS G12C-mutated NSCLC in want of first-line remedy is ongoing (CodeBreaK 201). 10 A Section 3 examine of LUMAKRAS plus carboplatin and pemetrexed as front-line remedy in KRAS G12C-mutant, programmed death-ligand 1 (PD-L1) destructive superior NSCLC is enrolling sufferers (CodeBreaK 202). A Section 3 examine of LUMAKRAS together with Vectibix and FOLFIRI in first-line KRAS G12C–mutated CRC can be enrolling sufferers (CodeBreak-301).
LUMAKRAS ® (sotorasib) U.S. Indication
LUMAKRAS is indicated for the remedy of grownup sufferers with KRAS G12C-mutated domestically superior or metastatic non-small cell lung most cancers (NSCLC), as decided by an FDA-approved take a look at, who have acquired no less than one prior systemic remedy.
This indication is accepted underneath accelerated approval primarily based on total response fee (ORR) and period of response (DOR). Continued approval for this indication could also be contingent upon verification and outline of scientific profit in a confirmatory trial(s).
LUMAKRAS ® (sotorasib) Essential U.S. Security Info
Hepatotoxicity
- LUMAKRAS may cause hepatotoxicity, which can result in drug-induced liver damage and hepatitis.
- Amongst 357 sufferers who acquired LUMAKRAS in CodeBreaK 100, hepatotoxicity occurred in 1.7% (all grades) and 1.4% (Grade 3). A complete of 18% of sufferers who acquired LUMAKRAS had elevated alanine aminotransferase (ALT)/elevated aspartate aminotransferase (AST); 6% had been Grade 3 and 0.6% had been Grade 4. Along with dose interruption or discount, 5% of sufferers acquired corticosteroids for the remedy of hepatotoxicity.
- Monitor liver perform assessments (ALT, AST and whole bilirubin) previous to the beginning of LUMAKRAS each 3 weeks for the primary 3 months of remedy, then as soon as a month or as clinically indicated, with extra frequent testing in sufferers who develop transaminase and/or bilirubin elevations.
- Withhold, scale back or completely discontinue LUMAKRAS primarily based on severity of opposed response.
Interstitial Lung Illness (ILD)/Pneumonitis
- LUMAKRAS may cause ILD/pneumonitis that may be deadly. Amongst 357 sufferers who acquired LUMAKRAS in CodeBreaK 100, ILD/pneumonitis occurred in 0.8% of sufferers, all circumstances had been Grade 3 or 4 at onset, and 1 case was deadly. LUMAKRAS was discontinued on account of ILD/pneumonitis in 0.6% of sufferers.
- Monitor sufferers for brand new or worsening pulmonary signs indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Instantly withhold LUMAKRAS in sufferers with suspected ILD/pneumonitis and completely discontinue LUMAKRAS if no different potential causes of ILD/pneumonitis are recognized.
Most Widespread Hostile Reactions
- The most typical opposed reactions occurring in ≥ 20% had been diarrhea, musculoskeletal ache, nausea, fatigue, hepatotoxicity and cough.
Drug Interactions
- Advise sufferers to tell their healthcare supplier of all concomitant medicines, together with prescription medicines, over-the-counter medication, nutritional vitamins, dietary and natural merchandise.
- Inform sufferers to keep away from proton pump inhibitors and H 2 receptor antagonists whereas taking LUMAKRAS.
- If coadministration with an acid-reducing agent can’t be averted, inform sufferers to take LUMAKRAS 4 hours earlier than or 10 hours after a domestically appearing antacid.
Please see LUMAKRAS full Prescribing Info .
About Vectibix ® (panitumumab)
Vectibix is the primary and solely absolutely human monoclonal anti-EGFR antibody accepted by the FDA for the remedy of mCRC. Vectibix was accepted within the U.S. in September 2006 as a monotherapy for the remedy of sufferers with EGFR-expressing mCRC after illness development after prior remedy with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy.
In Might 2014, the FDA accepted Vectibix to be used together with FOLFOX as first-line remedy in sufferers with wild-type KRAS (exon 2) mCRC. With this approval, Vectibix turned the first-and-only biologic remedy indicated to be used with FOLFOX, one of the crucial generally used chemotherapy regimens, within the first-line remedy of mCRC for sufferers with wild-type KRAS mCRC.
In June 2017, the FDA accepted a refined indication for Vectibix to be used in sufferers with wild-type RAS (outlined as wild-type in each KRAS and NRAS as decided by an FDA-approved take a look at for this use) mCRC.
INDICATION AND LIMITATION OF USE
Vectibix ® is indicated for the remedy of sufferers with wild-type RAS (outlined as wild-type in each KRAS and NRAS as decided by an FDA-approved take a look at for this use) metastatic colorectal most cancers (mCRC): as first-line remedy together with FOLFOX, and as monotherapy following illness development after prior remedy with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy.
Limitation of Use: Vectibix ® shouldn’t be indicated for the remedy of sufferers with RAS mutant mCRC or for whom RAS mutation standing is unknown.
IMPORTANT SAFETY INFORMATION
BOXED WARNING: DERMATOLOGIC TOXICITY
Dermatologic Toxicity: Dermatologic toxicities occurred in 90% of sufferers and had been extreme (NCI-CTC grade 3 and better) in 15% of sufferers receiving Vectibix monotherapy [see Dosage and Administration (2.3), Warnings and Precautions (5.1), and Adverse Reactions (6.1)].
- In Examine 20020408, dermatologic toxicities occurred in 90% of sufferers and had been extreme (NCI-CTC grade 3 and better) in 15% of sufferers with mCRC receiving Vectibix ® . The scientific manifestations included, however weren’t restricted to, acneiform dermatitis, pruritus, erythema, rash, pores and skin exfoliation, paronychia, dry pores and skin, and pores and skin fissures.
- Monitor sufferers who develop dermatologic or comfortable tissue toxicities whereas receiving Vectibix ® for the event of inflammatory or infectious sequelae. Life-threatening and deadly infectious problems together with necrotizing fasciitis, abscesses, and sepsis have been noticed in sufferers handled with Vectibix ® . Life-threatening and deadly bullous mucocutaneous illness with blisters, erosions, and pores and skin sloughing has additionally been noticed in sufferers handled with Vectibix ® . It couldn’t be decided whether or not these mucocutaneous opposed reactions had been straight associated to EGFR inhibition or to idiosyncratic immune- associated results (e.g., Stevens Johnson syndrome or poisonous epidermal necrolysis). Withhold or discontinue Vectibix ® for dermatologic or comfortable tissue toxicity related to extreme or life-threatening inflammatory or infectious problems. Dose modifications for Vectibix ® regarding dermatologic toxicity are supplied within the product labeling.
- Vectibix ® shouldn’t be indicated for the remedy of sufferers with colorectal most cancers that harbor somatic RAS mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146) of both KRAS or NRAS and hereafter is known as ” RAS. ”
- Retrospective subset analyses throughout a number of randomized scientific trials had been carried out to analyze the function of RAS mutations on the scientific results of anti-EGFR-directed monoclonal antibodies (panitumumab or cetuximab). Anti-EGFR antibodies in sufferers with tumors containing RAS mutations resulted in exposing these sufferers to anti-EGFR associated opposed reactions with out scientific profit from these brokers. Moreover, in Examine 20050203, 272 sufferers with RAS -mutant mCRC tumors acquired Vectibix ® together with FOLFOX and 276 sufferers acquired FOLFOX alone. In an exploratory subgroup evaluation , OS was shorter (HR = 1.21, 95% CI: 1.01-1.45) in sufferers with RAS -mutant mCRC who acquired Vectibix ® and FOLFOX versus FOLFOX alone.
- Progressively reducing serum magnesium ranges resulting in extreme (grade 3-4) hypomagnesemia occurred in as much as 7% (in Examine 20080763) of sufferers throughout scientific trials. Monitor sufferers for hypomagnesemia and hypocalcemia previous to initiating Vectibix ® remedy, periodically throughout Vectibix ® remedy, and for as much as 8 weeks after the completion of remedy. Different electrolyte disturbances, together with hypokalemia, have additionally been noticed. Replete magnesium and different electrolytes as applicable.
- In Examine 20020408, 4% of sufferers skilled infusion reactions and 1% of sufferers skilled extreme infusion reactions (NCI-CTC grade 3-4). Infusion reactions, manifesting as fever, chills, dyspnea, bronchospasm, and hypotension, can happen following Vectibix ® administration. Deadly infusion reactions occurred in postmarketing expertise. Terminate the infusion for extreme infusion reactions.
- Extreme diarrhea and dehydration, resulting in acute renal failure and different problems, have been noticed in sufferers handled with Vectibix ® together with chemotherapy.
- Deadly and nonfatal circumstances of interstitial lung illness (ILD) (1%) and pulmonary fibrosis have been noticed in sufferers handled with Vectibix ® . Pulmonary fibrosis occurred in lower than 1% (2/1467) of sufferers enrolled in scientific research of Vectibix ® . Within the occasion of acute onset or worsening of pulmonary signs interrupt Vectibix ® remedy. Discontinue Vectibix ® remedy if ILD is confirmed.
- In sufferers with a historical past of interstitial pneumonitis or pulmonary fibrosis, or proof of interstitial pneumonitis or pulmonary fibrosis, the advantages of remedy with Vectibix ® versus the danger of pulmonary problems have to be rigorously thought of.
- Publicity to daylight can exacerbate dermatologic toxicity. Advise sufferers to put on sunscreen and hats and restrict solar publicity whereas receiving Vectibix ® .
- Keratitis and ulcerative keratitis, recognized threat components for corneal perforation, have been reported with Vectibix ® use. Monitor for proof of keratitis or ulcerative keratitis. Interrupt or discontinue Vectibix ® for acute or worsening keratitis.
- In an interim evaluation of an open-label, multicenter, randomized scientific trial within the first-line setting in sufferers with mCRC, the addition of Vectibix ® to the mix of bevacizumab and chemotherapy resulted in decreased OS and elevated incidence of NCI-CTC grade 3-5 (87% vs 72%) opposed reactions. NCI-CTC grade 3-4 opposed reactions occurring at the next fee in Vectibix ® -treated sufferers included rash/acneiform dermatitis (26% vs 1%), diarrhea (23% vs 12%), dehydration (16% vs 5%), primarily occurring in sufferers with diarrhea, hypokalemia (10% vs 4%), stomatitis/mucositis (4% vs
- NCI-CTC grade 3-5 pulmonary embolism occurred at the next fee in Vectibix ® -treated sufferers (7% vs 3%) and included deadly occasions in three ( ® -treated sufferers. On account of the toxicities skilled, sufferers randomized to Vectibix ® , bevacizumab, and chemotherapy acquired a decrease imply relative dose depth of every chemotherapeutic agent (oxaliplatin, irinotecan, bolus 5-FU, and/or infusional 5-FU) over the primary 24 weeks on examine in contrast with these randomized to bevacizumab and chemotherapy.
- Vectibix ® may cause fetal hurt when administered to a pregnant lady. Advise pregnant girls and females of reproductive potential of the potential threat to a fetus. Advise females of reproductive potential to make use of efficient contraception throughout remedy, and for no less than 2 months after the final dose of Vectibix ® .
- In monotherapy, essentially the most generally reported opposed reactions (≥ 20%) in sufferers with Vectibix ® had been pores and skin rash with variable displays, paronychia, fatigue, nausea, and diarrhea.
- Essentially the most generally reported opposed reactions (≥ 20%) with Vectibix ® + FOLFOX had been diarrhea, stomatitis, mucosal irritation, asthenia, paronychia, anorexia, hypomagnesemia, hypokalemia, rash, acneiform dermatitis, pruritus, and dry pores and skin. The most typical severe opposed reactions (≥ 2% distinction between remedy arms) had been diarrhea and dehydration.
To see the Vectibix ® Prescribing Info, together with Boxed Warning go to www.vectibix.com .
About Amgen
Amgen discovers, develops, manufactures and delivers modern medicines to assist hundreds of thousands of sufferers of their struggle in opposition to a number of the world’s hardest illnesses. Greater than 40 years in the past, Amgen helped to determine the biotechnology trade and stays on the cutting-edge of innovation, utilizing expertise and human genetic knowledge to push past what’s recognized at present. Amgen is advancing a broad and deep pipeline that builds on its present portfolio of medicines to deal with most cancers, coronary heart illness, osteoporosis, inflammatory illnesses and uncommon illnesses.
In 2024, Amgen was named one of many “World’s Most Modern Firms” by Quick Firm and one in every of “America’s Greatest Giant Employers” by Forbes, amongst different exterior recognitions . Amgen is without doubt one of the 30 corporations that comprise the Dow Jones Industrial Common ® , and it is usually a part of the Nasdaq-100 Index ® , which incorporates the biggest and most modern non-financial corporations listed on the Nasdaq Inventory Market primarily based on market capitalization.
For extra data, go to Amgen.com and observe Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads .
Amgen Ahead-Wanting Statements
This information launch accommodates forward-looking statements which are primarily based on the present expectations and beliefs of Amgen. All statements, aside from statements of historic reality, are statements that could possibly be deemed forward-looking statements, together with any statements on the end result, advantages and synergies of collaborations, or potential collaborations, with another firm (together with BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the efficiency of Otezla ® (apremilast) (together with anticipated Otezla gross sales progress and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (together with the possible efficiency and outlook of Horizon’s enterprise, efficiency and alternatives, any potential strategic advantages, synergies or alternatives anticipated on account of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related bills going ahead), in addition to estimates of revenues, working margins, capital expenditures, money, different monetary metrics, anticipated authorized, arbitration, political, regulatory or scientific outcomes or practices, buyer and prescriber patterns or practices, reimbursement actions and outcomes, results of pandemics or different widespread well being issues on our enterprise, outcomes, progress, and different such estimates and outcomes. Ahead-looking statements contain vital dangers and uncertainties, together with these mentioned under and extra absolutely described within the Securities and Change Fee studies filed by Amgen, together with our most up-to-date annual report on Type 10-Ok and any subsequent periodic studies on Type 10-Q and present studies on Type 8-Ok. Until in any other case famous, Amgen is offering this data as of the date of this information launch and doesn’t undertake any obligation to replace any forward-looking statements contained on this doc on account of new data, future occasions or in any other case.
No forward-looking assertion could be assured and precise outcomes could differ materially from these we mission. Discovery or identification of recent product candidates or improvement of recent indications for present merchandise can’t be assured and motion from idea to product is unsure; consequently, there could be no assure that any specific product candidate or improvement of a brand new indication for an present product will probably be profitable and develop into a industrial product. Additional, preclinical outcomes don’t assure secure and efficient efficiency of product candidates in people. The complexity of the human physique can’t be completely, or generally, even adequately modeled by laptop or cell tradition techniques or animal fashions. The size of time that it takes for us to finish scientific trials and acquire regulatory approval for product advertising and marketing has up to now diversified and we count on comparable variability sooner or later.
Even when scientific trials are profitable, regulatory authorities could query the sufficiency for approval of the trial endpoints we now have chosen. We develop product candidates internally and thru licensing collaborations, partnerships and joint ventures. Product candidates which are derived from relationships could also be topic to disputes between the events or could show to be not as efficient or as secure as we could have believed on the time of coming into into such relationship. Additionally, we or others may determine security, uncomfortable side effects or manufacturing issues with our merchandise, together with our units, after they’re in the marketplace.
Our outcomes could also be affected by our potential to efficiently market each new and present merchandise domestically and internationally, scientific and regulatory developments involving present and future merchandise, gross sales progress of just lately launched merchandise, competitors from different merchandise together with biosimilars, difficulties or delays in manufacturing our merchandise and world financial circumstances. As well as, gross sales of our merchandise are affected by pricing stress, political and public scrutiny and reimbursement insurance policies imposed by third-party payers, together with governments, personal insurance coverage and managed care suppliers and could also be affected by regulatory, scientific and guideline developments and home and worldwide tendencies towards managed care and healthcare price containment. Moreover, our analysis, testing, pricing, advertising and marketing and different operations are topic to in depth regulation by home and overseas authorities regulatory authorities. Our enterprise could also be impacted by authorities investigations, litigation and product legal responsibility claims. As well as, our enterprise could also be impacted by the adoption of recent tax laws or publicity to extra tax liabilities. If we fail to satisfy the compliance obligations within the company integrity settlement between us and the U.S. authorities, we may develop into topic to vital sanctions. Additional, whereas we routinely get hold of patents for our merchandise and expertise, the safety provided by our patents and patent purposes could also be challenged, invalidated or circumvented by our opponents, or we could fail to prevail in current and future mental property litigation. We carry out a considerable quantity of our industrial manufacturing actions at a number of key amenities, together with in Puerto Rico, and likewise depend upon third events for a portion of our manufacturing actions, and limits on provide could constrain gross sales of sure of our present merchandise and product candidate improvement. An outbreak of illness or comparable public well being menace, corresponding to COVID-19, and the general public and governmental effort to mitigate in opposition to the unfold of such illness, may have a big opposed impact on the provision of supplies for our manufacturing actions, the distribution of our merchandise, the commercialization of our product candidates, and our scientific trial operations, and any such occasions could have a cloth opposed impact on our product improvement, product gross sales, enterprise and outcomes of operations. We depend on collaborations with third events for the event of a few of our product candidates and for the commercialization and gross sales of a few of our industrial merchandise. As well as, we compete with different corporations with respect to lots of our marketed merchandise in addition to for the invention and improvement of recent merchandise. Additional, some uncooked supplies, medical units and part components for our merchandise are provided by sole third-party suppliers. Sure of our distributors, clients and payers have substantial buying leverage of their dealings with us. The invention of great issues with a product just like one in every of our merchandise that implicate a complete class of merchandise may have a cloth opposed impact on gross sales of the affected merchandise and on our enterprise and outcomes of operations. Our efforts to collaborate with or purchase different corporations, merchandise or expertise, and to combine the operations of corporations or to help the merchandise or expertise we now have acquired, might not be profitable. There could be no assure that we will notice any of the strategic advantages, synergies or alternatives arising from the Horizon acquisition, and such advantages, synergies or alternatives could take longer to appreciate than anticipated. We could not be capable to efficiently combine Horizon, and such integration could take longer, be harder or price greater than anticipated. A breakdown, cyberattack or data safety breach of our data expertise techniques may compromise the confidentiality, integrity and availability of our techniques and our knowledge. Our inventory worth is unstable and could also be affected by various occasions. Our enterprise and operations could also be negatively affected by the failure, or perceived failure, of attaining our environmental, social and governance targets. The results of worldwide local weather change and associated pure disasters may negatively have an effect on our enterprise and operations. International financial circumstances could amplify sure dangers that have an effect on our enterprise. Our enterprise efficiency may have an effect on or restrict the flexibility of our Board of Administrators to declare a dividend or our potential to pay a dividend or repurchase our frequent inventory. We could not be capable to entry the capital and credit score markets on phrases which are favorable to us, or in any respect.
The scientific data mentioned on this information launch associated to our product candidates is preliminary and investigative. Such product candidates should not accepted by the U.S. Meals and Drug Administration, and no conclusions can or must be drawn concerning the protection or effectiveness of the product candidates. Additional, any scientific data mentioned on this information launch referring to new indications for our merchandise is preliminary and investigative and isn’t a part of the labeling accepted by the U.S. Meals and Drug Administration for the merchandise. The merchandise should not accepted for the investigational use(s) mentioned on this information launch, and no conclusions can or must be drawn concerning the protection or effectiveness of the merchandise for these makes use of.
CONTACT: Amgen, Thousand Oaks
Elissa Snook , 609-251-1407 (media)
Justin Claeys , 805-313-9775 (buyers)
References
- Rawla, P, et al. Gastroenterology Evaluate. 2019;14(2):89-103.
- World Well being Group. 2022 Statistics. Obtainable at: https://www.who.int/en/news-room/fact-sheets/element/most cancers . Accessed on Might 17, 2024 .
- Neumann J, et al. Frequency and kind of KRAS mutations in routine diagnostic evaluation of metastatic colorectal most cancers. Pathol Res Pract . 2009;205(12):858-862.
- Jones RP, et al. Particular mutations in KRAS codon 12 are related to worse total survival in sufferers with superior and recurrent colorectal most cancers. Br J Most cancers . 2017;116(7):923-929.
- Wiesweg M, et al. Influence of RAS mutation subtype on scientific outcome-a cross-entity comparability of sufferers with superior non-small cell lung most cancers and colorectal most cancers. Oncogene . 2019;38(16):2953-2966.
- Sung H, et al. CA Most cancers J Clin. 2021;71:209-249.
- Arbour KC, et al. Results of Co-occurring Genomic Alterations on Outcomes in Sufferers with KRAS- Mutant Non-Small Cell Lung Most cancers. Clin Most cancers Res . 2018;24:334-340.
- Nassar AF, et al. Distribution of KRAS G12C Somatic Mutations throughout Race, Intercourse, and Most cancers Sort. N Engl J. Med . 2021;384:185-187.
- ClinicalTrials.gov . CodeBreaK 101. Obtainable at: https://clinicaltrials.gov/ct2/present/NCT04185883 . Accessed on Might 7, 2024 .
- ClinicalTrials.gov . CodeBreaK 201. Obtainable at: https://clinicaltrials.gov/ct2/present/NCT04933695 . Accessed on Might 7, 2024 .
**These knowledge are a mixed evaluation of three research, one in every of which was not Amgen supported.
View authentic content material to obtain multimedia: https://www.prnewswire.com/news-releases/amgen-to-present-data-from-multiple-early-stage-clinical-trials-at-esmo-2024-302247205.html
SOURCE Amgen